Australia's most trusted
source of pharma news
Posted 24 January 2022 AM
There was an influx of medicines onto the ARTG last week with the TGA approving a range of products, including two new vaccines and three innovative therapeutics, most of which were provisionally ticked.
MSD's 15-valent pneumococcal conjugate vaccine Vaxneuvance which was recommended for listing on the National Immunisation Program in November ahead of TGA approval has been approved for use in adults 18 years of age and older.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.